ERS Genomics completes licensing agreement with Syngene International
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The company shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical and biological products of any kind
A special purpose vehicle (SPV) formed by O2 Energy SG Pte Ltd, for generation and supply of renewable power
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Singh previously served as Head of IT (Development and Manufacturing Services) at Syngene International Limited, Lead of IT Manufacturing at UPL, and AGM at The Hi-Tech Gears
His career spans notable tenures at Syngene International Limited, Cipla, Nestlé, and Bharat Petroleum Corporation Limited
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Subscribe To Our Newsletter & Stay Updated